Clinical Research

U.S. to lead global protein A resins market landscape over 2016-2024, technological advanced clinical infrastructure to drive the regional growth

Posted on

The increasing usage of monoclonal antibodies for therapeutic and diagnostic purposes will multiply Protein A resins market revenue in the years ahead. Industry players are focusing on manufacturing copious quantities of biosimilars to reduce the escalating medicine costs, which depicts a positive growth for the industry. Beneficial government norms supporting production of biosimilars will also spur the global demand for the products. As per Global Market Insights, Inc., “Protein A Resins Industry, which accumulated a revenue of USD 440 million in 2015, is slated to surpass USD 900 million by 2024.

Protein A resins are extensively used in antibody purification and immunoprecipitation processes. Antibody purification application segment is forecast to hit USD 700 million by 2024 and will contribute notably towards protein A resins industry size. Enhanced use of antibodies for diagnosing and treating dreaded diseases will push the revenue.

Immunoprecipitation, which contributed over 20% of protein A resins market share in 2015, is forecast to record a CAGR of 8% over the period of 2016 to 2024. Escalating usage of protein A resin products in purifying specified composites will help the industry to progress rapidly.

Japan Protein A Resin Market size, by matrix type, 2012-2024 (USD Million)
Japan Protein A Resin Market size, by matrix type, 2012-2024 (USD Million)

Contract research organizations, biopharmaceutical firms, academic research institutions, and clinical research institutes are the prominent end-use industries that extensively use protein A resins. Protein A resins market size from contract research organizations (CRO) is forecast to surpass USD 130 million by 2024, growing at an annual rate of 8.1% over 2016-2024. Massive outsourcing of protein purification processes by pharmaceutical & biotechnology firms and academic institutes will complement the growth.

Get a Sample Copy of this Report

Biopharmaceutical firms, which contributed more than 75% of protein A resins industry share in 2015, will hit a revenue margin of over USD 680 million by 2024. Global requirement for monoclonal antibodies for efficient diagnosis will augment the revenue.

Based on the product trends, protein A resins industry is classified into natural protein A resins and recombinant protein A resins. Natural protein A resins market is forecast to grow at a rate of 8% over 2016-2024 and will hit revenue of over USD 580 million by 2024. Highly beneficial product characteristics such as enhanced antibody production, convenient operation, and antibody purification will augment the growth.

Taking into consideration the regional trends, APAC protein A resins market is expected to record a CAGR of 8.5% over the period of 2016-2024. Beneficial legislations, reasonably developed healthcare infrastructure, and the easy availability of experts has prompted many CROs and biopharmaceutical firms to set up their business in the region. Japan protein A resins industry, worth USD 37 million in 2015, is intended to reach USD 78 million by 2024.

U.S. protein A resins industry, which accounted for over 85% of North America protein A resins market revenue in 2015, will witness a remarkable expansion over the coming years. A robust clinical infrastructure coupled with stringent government regulations regarding the usage of protein A resin products will play a vital role in shaping the business across the region.

Mexico protein A resins market is forecast to grow at a rate of 8% over the period of 2016-2024 and will drive the LATAM industry size. Growing use of monoclonal antibodies in clinical research activities is expected to impel the revenue.

Considering the matrix trends, protein A resins industry is segmented into organic polymer, agarose, and glass/silica gel. Agarose-based matrix, which contributed over 80% of protein A resins market size in 2015, is intended to record an annual growth of 8.3% over the period of 2016-2024, driven by ligand binding stability of this particular matrix. Silica gel based matrix is expected to register considerable gains of 8.4% over the coming seven years.

Strategic collaborations and product innovations are a couple of important business strategies adopted by leading companies to increase their return on sales and expand their business. Key industry participants include Danaher Corporation, Purolite Life Sciences, Novasep Holding SAS Company, GE Healthcare, Thermo Fisher Scientific, Bio-Rad Laboratories Incorporation, Sigma-Aldrich Corporation, GenScript Biotech Corporation, Agarose Bead Technologies, Takara Bio Incorporation, Expedeon Limited, and Merck Millipore Corporation.

Author Name :Dhananjay Punekar